Key clinical point: The novel dual IL-17A and -17F inhibitor bimekizumab achieves impressively rapid, large, and durable improvements in both PASI and DLQI.
Major finding: At 60 weeks of follow-up, 76%-93% of patients with a week-12 PASI90 response to various doses of bimekizumab had a DLQI score of 0 or 1.
Study details: This was a phase 2b, multicenter, double-blind clinical trial in which 250 psoriasis patients were randomized to various doses of bimekizumab or placebo for 60 weeks.
Disclosures: The presenter reported serving as a consultant to and recipient of research grants from study sponsor UCB Pharma.
Papp KA. EADV 2019 Abstract FC02.02.